Moogene Medi Company Description

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology.

The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus.

Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.

The company was founded in 2016 and is based in Hanam-si, South Korea.

Moogene Medi Co., Ltd.

Country	South Korea
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: Building C Hanam-si, 12939 South Korea
Phone	82 31 8027 6150
Website	moogene.com

Stock Details

Ticker Symbol	322970
Exchange	Korea New Exchange
Reporting Currency	KRW
SIC Code	2836